Developing a new class of biologics to break the cycle of injury and inflammation
AIRWAY THERAPEUTICS
Airway Therapeutics is developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases.
AT-100
AT-100 is the novel recombinant human protein rhSP-D – an engineered version of the endogenous protein hSP-D – that reduces inflammation and infection while modulating the immune response to break the cycle of injury and inflammation.
WHAT IS BPD?
Bronchopulmonary dysplasia is a ventilation and infection-induced respiratory disease with 200,000 very preterm infants at risk in the U.S. and Europe each year. Globally, about 2.5 million very pre-term infants are at-risk annually. BPD creates long-term lung damage that can lead to pro-longed NICU stays, a range of co-morbidities, lifelong chronic consequences and even death.
the latest news
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
Airway Therapeutics Announces First Patient Dosed in Phase 1b Trial of AT-100 in Severe COVID-19 Patients
Airway Therapeutics Announces FDA Acceptance of IND for AT-100’s Second Indication in Severe COVID-19 Patients
Airway Therapeutics Announces FDA Acceptance of IND for AT-100 in Preterm Infants at Risk for Bronchopulmonary Dysplasia (BPD)
CONTACT
For members of the scientific/medical and investment communities,
contact us at the link below by filling out our inquiry form.
